JFK Communications Adds Vicus Therapeutics to Client Roster

Vicus Therapeutics Developing Immuno-Oncology Product – VT-122 for the Treatment of Liver Cancer and Other Malignancies

SKILLMAN, NJ, April 9, 2015 JFK Communications, Inc. announced today the firm has added NJ-based Vicus Therapeutics, Inc. (www.vicusrx.com) to its growing roster of healthcare clients.   

JFK Communications will provide various strategic communications support to Vicus, including digital communications, corporate communications, and clinical data communications. 

“Vicus is a natural partner for JFK Communications considering our extensive immuno-oncology experience,” said John F. Kouten, CEO, JFK Communications, Inc. “Vicus is on the cutting edge of immuno-oncology through the development of VT-122, an immunotherapy in development for liver cancer.”

Vicus is employing immunotherapy to selectively target signaling pathways that lead to tumor-promoting inflammation and tumor evasion of the immune system. Their goal is to safely and significantly extend the clinical benefit of proven cancer therapies.


About JFK Communications

JFK Communications provides strategic communications solutions for the life science, healthcare and medical technology industries. Our communications services add value to our clients’ corporate images, strengthen their brands, and improve the lives of customers, patients and communities throughout the world. Please visit the JFK website at www.jfkhealth.com, or call us at (609) 456-0822.


About Vicus Therapeutics

Vicus Therapeutics is an immuno-oncology company bringing breakthrough immunotherapies to patients with solid-tumor cancers. Vicus is focused on the development and commercialization of its lead product VT-122, a novel chrono-modulated formulation of etodolac and propranolol. VT-122 targets onco-inflammation and is designed to synergistically damp tumor-promoting inflammation and restore a tumor-suppressing immune state. VT-122 is currently being investigated in combination with sorafenib in a Phase 2 clinical study of patients with advanced liver cancer and in combination with standard-of-care anticancer therapies in investigator-initiated studies of pancreatic, gallbladder, and other solid-tumor cancers.